Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770326 | 0.85 | CYP11B1 (0.39) | NR1H4NPBWR1MCHR1KMT2APOLB | |
| SCHEMBL2789889 | 0.77 | CCR1 (0.38) | ALDH1A1 | |
| SCHEMBL19810784 | 0.76 | NR1H4 (0.42) | NR1H4NPSR1POLBGAANR4A2 | |
| SCHEMBL28801576 | 0.76 | NR1H4 (0.38) | NR1H4NPBWR1MCHR1KMT2AGAA | |
| SCHEMBL1095989 | 0.72 | NR1H4 (0.46) | NR1H4NPBWR1MCHR1KMT2AMAPK14 | |
| SCHEMBL20094462 | 0.72 | NR1H4 (0.40) | NR1H4NPBWR1MCHR1KMT2ALIMK1 | |
| SCHEMBL497932 | 0.71 | NPSR1 (0.45) | NPSR1POLBGAANR4A2ALDH1A1 | |
| SCHEMBL2772485 | 0.71 | KCNK3 (0.42) | NPBWR1MCHR1KMT2AALDH1A1MAPK14 | |
| SCHEMBL2774647 | 0.71 | NR1H4 (0.45) | NR1H4NPBWR1MCHR1ALDH1A1MAPK14 | |
| SCHEMBL26272107 | 0.70 | NR1H4 (0.43) | NR1H4NPBWR1MCHR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899723-B2 | Heterocyclic containing cyclopropyl FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-01-26 | — | — | US | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| WO-2018075207-A1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS, INC. (VG) | 2018-04-26 | — | — | WO | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899723-B2 | Heterocyclic containing cyclopropyl FXR modulators | NR1H4, FXR1, GPBAR1 | NR1H4 1/4885NPBWR1 703/4885MCHR1 2013/4885 |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | NR1H4, FXR1, NR1H2 | NR1H4 1/4885NPBWR1 506/4885MCHR1 2014/4885 |
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR1H4 1/4885NPBWR1 348/4885MCHR1 1417/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885NPBWR1 532/4885MCHR1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.